Clinical trials: Proliferative Diabetic Retinopathy (PDR)
Diabetic Retinopathy
Extension Study of the Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy
This multicenter, open-label extension study will evaluate the long-term tolerability and safety for patients completing study CSMS995 0802.
- Trial name
- NCT00248157
- Testing
- Octreotide acetate in microspheres
- Volunteers
- 105 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Retinopathy
HORNBILL: A Study to Test Different Doses of BI 764524 in Patients Who Have Had Laser Treatment for a Type of Diabetic Eye Disease Called Diabetic Retinopathy With Diabetic Macular Ischemia
This is a study in people with a type of diabetic eye disease called diabetic retinopathy with diabetic macular ischemia. People who have had laser treatment for their diabetic retinopathy can participate in the study.
- Trial name
- HORNBILL (NCT04424290)
- Testing
- BI 764524
- Where
- 19 sites in United States, United Kingdom
- Volunteers
- 45 people
- Sponsor
- Boehringer Ingelheim
Diabetic Retinopathy
Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy
The most common ocular disease in patients with diabetes, diabetic retinopathy, is present in approximately 40% of diabetic patients; about 8% of diabetic patients have vision threatening diabetic retinopathy.
- Trial name
- NCT00130845
- Testing
- Octreotide Acetate in Microspheres
- Where
- United States
- Volunteers
- 312 people
- Sponsor
- Novartis
Diabetic Retinopathy, Diabetic Macular Edema
Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy
The objective of this study is to evaluate the safety and efficacy of APX3330 to treat diabetic retinopathy (DR) and diabetic macular edema (DME).
- Conditions
- Diabetic Retinopathy, Diabetic Macular Edema, NPDR - Non Proliferative Diabetic Retinopathy, PDR - Proliferative Diabetic Retinopathy
- Trial name
- ZETA-1 (NCT04692688)
- Testing
- APX3330
- Where
- 24 sites in United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Opus Genetics, Inc
Diabetic Retinopathy
Extension Study of Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy
This multicenter, open-label extension study will evaluate the long-term tolerability and safety for patients completing study CSMS995 0802.
- Trial name
- NCT00248131
- Testing
- Octreotide acetate in microspheres
- Volunteers
- 260 people
- Sponsor
- Novartis Pharmaceuticals
Proliferative Diabetic Retinopathy (PDR)
Phase I Study Assessing the Ocular and Systemic Safety and Tolerability of OC-10X
The present study is intended to evaluate the safety and tolerability of topical OC-10X Ophthalmic Suspension in healthy human subjects. OcuCure Therapeutics, Inc.
- Trial name
- NCT01869933
- Testing
- OC-10X
- Where
- Bangladesh
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- OcuCure Therapeutics, Inc.
Proliferative Diabetic Retinopathy (PDR)
Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE)
The purpose of this study was to assess the efficacy and safety of the anti-Vascular Endothelial Growth Factor (VEGF) agent ranibizumab (0.5 mg) with or without Panretinal laser photocoagulation (PRP) compared to PRP alone in…
- Trial name
- PRIDE (NCT01594281)
- Testing
- Ranibizumab 0.5 mg, Panretinal laser photocoagulation
- Where
- 23 sites in Germany
- Volunteers
- 107 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Retinopathy
Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy
The most common ocular disease in patients with diabetes, diabetic retinopathy, is present in approximately 40% of diabetic patients; about 8% of diabetic patients have vision threatening diabetic retinopathy.
- Trial name
- NCT00131144
- Testing
- Octreotide Acetate in Microspheres 20 mg, Octreotide Acetate in Microspheres
- Where
- United States
- Volunteers
- 583 people
- Sponsor
- Novartis
Visual Impairment Due to Diabetic Macular Edema
Safety and Efficacy of Ranibizumab in Diabetic Macular Edema
This study was designed to confirm the efficacy and safety of laser photocoagulation as adjunctive therapy to ranibizumab 0.5 mg versus laser monotherapy in patients with visual impairment due to Diabetic Macular Edema.
- Trial name
- RELATION (NCT01131585)
- Testing
- Active laser photocoagulation, Ranibizumab 0.5 mg
- Where
- 34 sites in Germany
- Volunteers
- 128 people
- Sponsor
- Novartis Pharmaceuticals
Proliferative Diabetic Retinopathy
Study to Assess the Efficacy and Safety of Monthly Octreotide Intramuscular Injections in Patients With Proliferative Diabetic Retinopathy After Lasercoagulation This Study is Not Being Conducted in the United States.
Phase III study comparing monthly octreotide i.m. in comparison to no additional treatment in patients with proliferative diabetic retinopathy after lasercoagulation.
- Trial name
- NCT00170742
- Testing
- Octreotide, 30 mg i.m. LAR formulation
- Where
- Switzerland
- Volunteers
- 17 people
- Sponsor
- Novartis
Proliferative Diabetic Retinopathy (PDR)
A Study Assessing Efficacy and Safety of OC-10X in the Treatment of PDR
The present study is intended to evaluate the efficacy and safety of topical OC-10X Ophthalmic Suspension in patients diagnosed with proliferative diabetic retinopathy (level 61, 65, 71, or 75). OcuCure Therapeutics, Inc.
- Trial name
- NCT02735369
- Testing
- 2% OC-10X
- Where
- Bangladesh
- Volunteers
- 40 people
- Sponsor
- OcuCure Therapeutics, Inc.
Diabetic Retinopathy
Study of Topical Ocular PAN-90806 in PDR
The objective of this study is to assess the safety and tolerability of topical ocular PAN-90806 in patients with proliferative diabetic retinopathy.
- Trial name
- NCT02475109
- Testing
- PAN-90806 Ophthalmic Solution
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- PanOptica, Inc.